Japanese Patients Show Promise with Asciminib
Asciminib is a drug that has been making waves in the treatment of chronic myeloid leukemia (CML). The ASC4FIRST study is a phase III trial that compared asciminib with other tyrosine kinase inhibitors (TKIs) chosen by doctors. The results were impressive, showing that asciminib was more effective